Quarterly report [Sections 13 or 15(d)]

Segment Reporting

v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 7 – Segment Reporting

 

We manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our chief operating decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net loss.

 

The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the three months ended March 31, 2025 and 2024:

    2025     2024  
    Three months ended March 31,  
    2025     2024  
Preclinical, clinical trial and other costs   $ 1,197,035     $ 1,031,280  
Research and development personnel expense(1)     391,505       507,790  
General and administrative personnel expense(2)     673,779       518,831  
Administrative and facilities expense(3)     584,671       751,697  
Other income, net     (12,585 )     (83,217 )
Total   $ 2,834,405     $ 2,726,381  

  

(1) Research and development personnel costs include employee stock-based compensation expense of $46,720 and $31,121 for the three months ended March 31, 2025 and 2024, respectively.
(2)   General and administrative personnel costs include employee stock-based compensation expense of $122,655 and $38,871 for the three months ended March 31, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC.
(3)   Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.